Evidence map›Paper›PMID 31085405›Full record

ReviewCurrent opinion in microbiology2019

Candida albicans biofilm growth and dispersal: contributions to pathogenesis.

Gina Wall, Daniel Montelongo-Jauregui, Bruna Vidal Bonifacio, Jose L Lopez-Ribot, Priya Uppuluri

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed
16.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 251 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Roles of Indole and Its Derivative in ModulatingInternational journal of molecular sciences · 2026
    Article
  7. Article
  8. Journal of fungi (Basel, Switzerland) · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. OvercomingFrontiers in antibiotics · 2026
    Review
  15. The roles ofFrontiers in medicine · 2026
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Gina WallDepartment of Biology and South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA.
Daniel Montelongo-JaureguiDepartment of Biology and South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA.
Bruna Vidal BonifacioDepartment of Biology and South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA.
Jose L Lopez-RibotDepartment of Biology and South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX 78249, USA. Electronic address: jose.lopezribot@utsa.edu.
Priya UppuluriDivision of Infectious Diseases, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA, 90509, USA. Electronic address: puppuluri@labiomed.org.
Texas Center for Infectious Disease · USThe University of Texas at San Antonio · USUCLA Medical Center · US

Funding

Development of novel chemical series of Candida albicans biofilm inhibitorsR01AI119554 · NIAID · UNIVERSITY OF TEXAS SAN ANTONIO · PI LOPEZ-RIBOT, JOSE L., MCHARDY, STANTON FURST · 2015 to 2019
$1.8M
Targeting virulence against oral candidiasis in HIV/AIDSR01DE023510 · NIDCR · UNIVERSITY OF TEXAS SAN ANTONIO · PI LOPEZ-RIBOT, JOSE L. · 2013 to 2017
$1.8M
Targeting the regulatory mechanism of hyphae to lateral yeast growth as a novel therapeutic approach against candidiasisR01AI141794 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI UPPULURI, PRIYA · 2019 to 2022
$1.5M
Development of Immunotherapeutic Strategies to Overcome Neonatal CandidiasisR21HD097480 · NICHD · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI UPPULURI, PRIYA · 2019 to 2020
$446k
NIAID NIH HHS R01 AI119554NIAID NIH HHS R01 AI141794NICHD NIH HHS R21 HD097480NIDCR NIH HHS R01 DE023510
6 · The paper itself

Abstract

The fungal species Candida albicans is most frequently associated with biofilm formation in immune-compromised and medically compromised patients, and it is now firmly established that biofilm formation represents a major virulence factor during candidiasis. A growing body of evidence has demonstrated that C. albicans biofilm development is a highly regulated and coordinated process, where adhesive interactions, morphogenetic conversions, and consortial behavior play significant roles. Cells within the biofilms are protected from environmental stresses including host immune defenses and antifungal treatment, which carries important clinical consequences for the treatment of biofilm-associated infections. Dispersal of cells from biofilms represents one of the hallmarks of the biofilm life-style, and in the case of C. albicans dispersed cells are responsible for candidemia and dissemination leading to the establishment of invasive disease.

Indexed as

AnimalsBiofilmsCandida albicansCandidiasisHumansVirulence

Identifiers

PMID31085405
PMCPMC6842673
OpenAlexW2946908776

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.